nach oben

Erschienen in:

01.06.2013 | Clinical Study

Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution

verfasst von: Pei Yang, Yongzhi Wang, Xiaoxia Peng, Gan You, Wei Zhang, Wei Yan, Zhaoshi Bao, Yinyan Wang, Xiaoguang Qiu, Tao Jiang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

To analyze the clinical characteristics and prognostic factors in patients with glioma in an academic institute in China. From October 2004 to August 2010, total 1,285 patients were diagnosed as glioma at the Glioma Center of Beijing Tiantan Hospital. Clinical and molecular pathology features and survival rates were analyzed. The median overall survival (OS) times were 78.1, 37.6 and 14.4 months for low-grade glioma (WHO grade II), anaplastic glioma (WHO grade III) and glioblastoma (WHO grade IV), respectively. In patients with low-grade glioma, age, preoperative Karnofsky performance scale (KPS), pathological type, radiotherapy, O⁶-methylguanine-DNA methyltransferase (MGMT) expression and Ki-67 expression, were significantly associated with OS in multivariate analyses; and preoperative KPS and radiotherapy were significantly associated with progression-free survival (PFS). For anaplastic gliomas, age, preoperative KPS, pathological type, extent of resection, radiotherapy, p53 expression and phosphatase and tensin homolog (PTEN) expression were associated with OS. For glioblastomas, age, preoperative KPS, pathology type, extent of resection, radiotherapy and chemotherapy were associated with OS; and age, gender, preoperative KPS, extent of resection, radiotherapy and chemotherapy were associated with PFS. This is the largest survey for glioma management in China to date. We found significant differences in age, presenting symptoms and the expression of p53, MGMT, PTEN, and Ki-67 among patients with different types of glioma. Age, preoperative KPS, tumor grades, radiotherapy, chemotherapy and Ki-67 expression were significantly associated with clinical prognosis.

Nur mit Berechtigung zugänglich

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93–108. doi:10.1007/s00401-005-0991-y PubMedCrossRef

Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde registry for the period 2000–2007. Neuro-Oncology 13(12):1370–1378. doi:10.1093/neuonc/nor120 PubMedCrossRef

Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F (2011) National comprehensive cancer network clinical practice guidelines in oncology: head and neck cancers. J Natl Compr Cancer Netw (JNCCN) 9(6):596–650

Stupp R, Pavlidis N, Jelic S (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16(Suppl 1):i64–i65. doi:10.1093/annonc/mdi834 PubMedCrossRef

Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER (2005) Patterns of care for adults with newly diagnosed malignant glioma. J Am Med Assoc (JAMA) 293(5):557–564. doi:10.1001/jama.293.5.557 CrossRef

Thurnher MM (2009) 2007 World Health Organization classification of tumours of the central nervous system. Cancer imaging: the official publication of the International Cancer Imaging Society 9 Spec No. A:S1–3. doi:10.1102/1470-7330.2009.9001

Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neuro-Oncol 58(3):217–236CrossRef

Brell M, Tortosa A, Verger E, Gil JM, Vinolas N, Villa S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of o ⁶-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11(14):5167–5174. doi:10.1158/1078-0432.CCR-05-0230 PubMedCrossRef

Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broet P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58(2):322–326. doi:10.1002/ana.20543 PubMedCrossRef

10.

Stupp R, Roila F (2009) Malignant glioma: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):126–128. doi:10.1093/annonc/mdp151 PubMed

11.

Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, Krengli M, Maluta S, Parisi S, Bertoni F, Mantovani C, Tombolini V, De Renzis C, Lioce M, Fatigante L, Fusco V, Muto P, Berti F, Rubino G, Cipressi S, Fariselli L, Lupattelli M, Santoni R, Pirtoli L, Biti G (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67(2):446–458. doi:10.1227/01.NEU.0000371990.86656.E8 PubMedCrossRef

12.

Kang SG, Kim JH, Nam DH, Park K (2005) Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol medico-chirurgica 45(5):232–238 discussion 238–239CrossRef

13.

Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003) Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129(8):477–484. doi:10.1007/s00432-003-0471-5 PubMedCrossRef

14.

Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M (2008) Multivariate analysis of prognostic factors and survival in patients with “glioblastoma multiforme”. La Clin terap 159(4):233–238

15.

You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Song YJ, Kang CS, Jiang T (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro-Oncology 14(2):230–241. doi:10.1093/neuonc/nor205 PubMedCrossRef

16.

Li S, Jiang T, Li G, Wang Z (2008) Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res 30(6):567–570. doi:10.1179/174313208X297913 PubMedCrossRef

17.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol 9(1):29–38. doi:10.1016/S1470-2045(07)70384-4 PubMedCrossRef

18.

Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T (2012) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. doi:10.1002/cncr.27826

19.

Zhang W, Yan W, You G, Bao Z, Wang Y, Liu Y, You Y, Jiang T (2013) Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. Cancer Lett 328(1):120–125. doi:10.1016/j.canlet.2012.08.033 PubMedCrossRef

20.

Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T (2012) Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology 14(12):1432–1440. doi:10.1093/neuonc/nos263 PubMedCrossRef

21.

Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-Oncology 14(4):518–525. doi:10.1093/neuonc/nor232 PubMedCrossRef

22.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-Oncology 14(1):109–116. doi:10.1093/neuonc/nor185 PubMedCrossRef

23.

Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, Wang Y, Song Y, Li Y, Jiang T, Pu P, Jiang C, Kang C (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-Oncology 14(8):1026–1036. doi:10.1093/neuonc/nos122 PubMedCrossRef

24.

Zhang J, Huang K, Shi Z, Zou J, Wang Y, Jia Z, Zhang A, Han L, Yue X, Liu N, Jiang T, You Y, Pu P, Kang C (2011) High beta-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro-Oncology 13(6):600–609. doi:10.1093/neuonc/nor034 PubMedCrossRef

25.

Burton EC, Prados MD (2000) Malignant gliomas. Curr Treat Options Oncol 1(5):459–468PubMedCrossRef

26.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198. doi:10.3171/jns.2001.95.2.0190 PubMedCrossRef

27.

Sawaya R (1999) Extent of resection in malignant gliomas: a critical summary. J Neuro-Oncol 42(3):303–305CrossRef

28.

Li S, Zhang W, Chen B, Jiang T, Wang Z (2010) Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. Neurol Res 32(7):690–694. doi:10.1179/016164109X12478302362536 PubMedCrossRef

29.

Westermark B (2012) Glioblastoma–a moving target. Upsala J Med Sci 117(2):251–256. doi:10.3109/03009734.2012.676574 PubMedCrossRef

30.

Fedrigo CA, Grivicich I, Schunemann DP, Chemale IM, dos Santos D, Jacovas T, Boschetti PS, Jotz GP, Braga AF, da Rocha AB (2011) Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol 6:156. doi:10.1186/1748-717X-6-156 PubMedCrossRef

31.

Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology 14(6):712–719. doi:10.1093/neuonc/nos089 PubMedCrossRef

32.

Hagerstrand D, Lindh MB, Pena C, Garcia-Echeverria C, Nister M, Hofmann F, Ostman A (2010) PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology 12(9):967–975. doi:10.1093/neuonc/noq029 PubMedCrossRef

33.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129–1133. doi:10.1038/nature07443 PubMedCrossRef

34.

Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67(17):7960–7965. doi:10.1158/0008-5472.CAN-07-2154 PubMedCrossRef

35.

Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A (2006) High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66(15):7429–7437. doi:10.1158/0008-5472.CAN-06-0712 PubMedCrossRef

36.

Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG, Merlo A (1999) The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59(21):5479–5482PubMed

37.

Paulus W (2009) GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol 118(5):603–604. doi:10.1007/s00401-009-0600-6 PubMedCrossRef

38.

Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273PubMedCrossRef

39.

Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. doi:10.1016/S1470-2045(12)70265-6 PubMedCrossRef

40.

Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J obstet Gynecol 206(2):e119–e121. doi:10.1016/j.ajog.2011.12.003 CrossRef

41.

Grossman SA, O’Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21(8):1485–1491. doi:10.1200/JCO.2003.10.035 PubMedCrossRef

42.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef

43.

Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88(12):2887PubMedCrossRef

44.

Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC (2012) Relative survival of patients with supratentorial low-grade gliomas. Neuro-Oncology 14(8):1062–1069. doi:10.1093/neuonc/nos144 PubMedCrossRef

45.

Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489PubMed

Titel: Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution
verfasst von: Pei Yang
Yongzhi Wang
Xiaoxia Peng
Gan You
Wei Zhang
Wei Yan
Zhaoshi Bao
Yinyan Wang
Xiaoguang Qiu
Tao Jiang
Publikationsdatum: 01.06.2013
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1103-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Interferon regulatory factor 3 alters glioma inflammatory and invasive properties

Single-nucleotide polymorphisms of allergy-related genes and risk of adult glioma

Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth

The role of the CXCR4 cell surface chemokine receptor in glioma biology

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide